Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total

Not Applicable (2)

Trial Status

Recruiting2

Terminated1

Not Yet Recruiting1

Active Not Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials

NCT07837349Not Yet Recruiting

Evaluation of the Clinical Value of NT-proBNP (or BNP) Measurement, Alone or in Combination With the EPOF Questionnaire, for the Screening of Chronic Heart Failure (CHF) in Adults Aged 40 Years and Older Referred for a Cardiology Consultation Without Suspected CHF.

NCT07599540Active Not Recruiting

Cardiovascular Risk in Peripheral Artery Disease Patients Undergoing Endovascular Revascularisation

NCT07343895Not ApplicableRecruiting

Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study

NCT07013344Recruiting

Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease

NCT03107390Not ApplicableTerminated

Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease

Showing all 5 trials